Malcolm Salter is Director at C4 Therapeutics, Inc. (CCCC). They have made 1 open-market trade across 1 company since 2020, most recently 2022-01-04.
CIK 0001825124
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $25K since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CCCC | 11,380 | $31K |
Shares reported on the most recent Form 4, priced at the 2022-01-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CCCC | SELL · 10b5-1 | 2021-12-17 | 2021-12-17 | $30.25 | $23K | +7.2% | -16.9% | -21.8% |
| CCCC | SELL · 10b5-1 | 2021-11-19 | 2021-11-19 | $40.11 | $30K | -9.3% | -19.2% | -43.0% |
| CCCC | SELL · 10b5-1 | 2021-10-15 | 2021-10-15 | $44.94 | $34K | +3.5% | -4.2% | -37.9% |
| CCCC | SELL · 10b5-1 | 2021-09-17 | 2021-09-21 | $49.89 | $38K | -8.4% | -12.3% | -37.2% |
| CCCC | SELL · 10b5-1 | 2021-08-20 | 2021-08-24 | $40.73 | $31K | +9.4% | +25.2% | -8.2% |
| CCCC | SELL · 10b5-1 | 2021-07-16 | 2021-07-19 | $37.37 | $28K | +10.5% | +1.0% | +8.7% |
| CCCC | SELL · 10b5-1 | 2021-06-18 | 2021-06-21 | $37.19 | $28K | +0.2% | +3.7% | +25.6% |
| CCCC | SELL · 10b5-1 | 2021-05-21 | 2021-05-24 | $37.12 | $28K | +4.4% | +1.0% | +12.0% |
| CCCC | BUY | 2020-10-06 | 2020-10-06 | $19.00 | $25K | -8.1% | -5.5% | +16.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.